Sio Partners Targets Cancer Treatments and SPACs for Growth – ValueWalk Premium
Sio Partners

Sio Partners Targets Cancer Treatments and SPACs for Growth

Sio Partners, the specialist healthcare hedge fund, returned 0.9% net of fees and expenses in January, compared to a loss of -1% for the S&P 500 and a gain of 1% for the MSCI World Healthcare Index. Long investments contributed 12.6%, according to a copy of the firm's letter, which ValueWalk has been able to review, while short positions detracted -10.7% from the performance.

Q4 2020 hedge fund letters, conferences and more

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The top investors are reading ValuewalkPremium.

Click here to learn why

0